2020
DOI: 10.4187/respcare.07849
|View full text |Cite
|
Sign up to set email alerts
|

Neuromuscular Blocking Agents for ARDS: A Systematic Review and Meta-Analysis

Abstract: BACKGROUND: Studies evaluating neuromuscular blocking agents (NMBAs) in the management of ARDS have produced inconsistent results in terms of their effect on mortality. The purpose of this systematic review and meta-analysis was to evaluate differences in mortality comparing subjects with ARDS who received NMBA to those who received placebo or usual care. METHODS: We searched Ovid, MEDLINE, Embase, CINAHL, Cochrane, Scopus, and Web of Science for randomized controlled trials evaluating administration of NMBAs … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(16 citation statements)
references
References 31 publications
0
15
0
1
Order By: Relevance
“…Em metanálise publicada por Torbic, et al, (2021), os autores descrevem que embora o uso do bloqueador neuromuscular tenha reduzido o risco de mortalidade a curto prazo, risco de barotrauma e pneumotórax, não foi encontrado o mesmo resultado na análise de mortalidade a longo prazo (90 dias) em comparação com o grupo controle.…”
Section: Resultsunclassified
“…Em metanálise publicada por Torbic, et al, (2021), os autores descrevem que embora o uso do bloqueador neuromuscular tenha reduzido o risco de mortalidade a curto prazo, risco de barotrauma e pneumotórax, não foi encontrado o mesmo resultado na análise de mortalidade a longo prazo (90 dias) em comparação com o grupo controle.…”
Section: Resultsunclassified
“…This necessitates that both patients are sedated and paralysed. Paralysis is not helpful beyond short time-frames [27] in a critical care patient, and the risk of undue muscular atrophy must be carefully considered when embarking on a course of care that necessitates paralysis. An ideal solution would allow the titration of as many respiratory parameters as possible, could respond to changes in lung mechanics of patients, and accommodate as wide a range of patients as possible, whilst facilitating lung protective ventilation.…”
Section: Discussionmentioning
confidence: 99%
“…The use of neuromuscular blockade (NMB) in patients with moderate to severe ARDS is associated with improved oxygenation, decreased ventilator associated lung injury, and improved mortality at 28 days, without increasing the incidence of neuromuscular weakness. 55 The most recent multicenter trial of NMB in ARDS (ROSE, data from which is included in reference 55), did not demonstrate a mortality benefit compared to a control group which only used light sedation, so routine use of NMB has been called into question. NMB use does require deep sedation, which is associated with increased mortality even after accounting for severity of illness, so this strategy must be employed cautiously.…”
Section: Diagnosismentioning
confidence: 99%